The European Medicines Agency (EMA) publishes a new factsheet on orphan medicines in the EU
Launched in 2000 the EU´s orphan designation program encourages research and development of medicines for rare diseases.
To date, over 1,900 medicines have been designated as orphan medicines, giving access to specific incentives that make it more attractive for companies to develop them. By the end of 2017, over 140 of these have entered the market, providing treatment options for patients suffering diseases for which previous therapies were suboptimal or nonexistent.
The new factsheet briefly explains what rare diseases are, how the EU program works and what incentives are made available to developers. It can be downloaded from the EMA´s website following this link.